Goldman Sachs analyst Chris Shibutani raised the price target on Royalty Pharma (NASDAQ: RPRX) to $50.00 (from $47.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE